David Critchley

Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist

Allan Fletcher, Elaine A. Forster, David J. Bill et al. · Behavioural Brain Research · 1995 · 521 citations

Medicine, Neuroscience, Pharmacology +13

Rufinamide: Clinical pharmacokinetics and concentration–response relationships in patients with epilepsy

Emilio Perucca, James C. Cloyd, David Critchley et al. · Epilepsia · 2008 · 258 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +11

Species variation in hepatic aldehyde oxidase activity

Christine Beedham, Sally Bruce, David Critchley et al. · European Journal of Drug Metabolism and Pharmacokinetics · 1987 · 96 citations

Life Sciences, Biochemistry, Enzymology +13

Substrate Specificity of Human Liver Aldehyde Oxidase toward Substituted Quinazolines and Phthalazines: A Comparison with Hepatic Enzyme from Guinea Pig, Rabbit, and Baboon

Christine Beedham, David Critchley, David J. Rance · Archives of Biochemistry and Biophysics · 1995 · 96 citations

Life Sciences, Biochemistry, Enzyme Mechanism +8

A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects

Julie C. Crockett, David Critchley, Bola Tayo et al. · Epilepsia · 2020 · 74 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17